Joe, I couldn't jump on the conf call but it looks like it went well. Question on one the the trials for Kiromic: can rapid mist be used on this one?
"BSK02 utilizes a microparticle delivery system (particles many times smaller than a single grain of sand) and activates the patient’s T-cells in a way that has never before been accomplished with an oral formulation. This promising therapy is already supported by an NIH grant, and an Orphan Drug Designation (ODD) from the FDA."
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.